Key result
Multifactorial primary prevention fails to reduce long-term mortality despite improving risk factors.
Why the study?
Multifactorial primary prevention trials have shown inconsistent in-trial prevention and diminished long-term benefits on risk factors and mortality, raising concerns about treatment effects.
Does multifactorial primary prevention reduce long-term total and coronary mortality in patients at risk for cardiovascular diseases?
Population
Patients in multifactorial primary prevention trials for cardiovascular diseases
Comparison
Multifactorial primary prevention including pharmacological treatments vs control subjects
Design
Review
Follow-up
Long term including post-trial periods
Authors
Loading...
Warrants caution against assuming long-term survival gains; leaves open optimal intervention selection and sustained follow-up needs.
Does multifactorial primary prevention reduce long-term total and coronary mortality in patients at risk for cardiovascular diseases?
Multifactorial primary prevention trials have shown disappointing long-term mortality outcomes, highlighting the need to carefully select pharmacological interventions to ensure benefit outweighs harm.
Miettinen et al. (1992) conducted a review in Cardiovascular diseases. Multifactorial primary prevention was evaluated on Total and coronary mortality. Multifactorial primary prevention of cardiovascular diseases has yielded disappointing long-term mortality results despite significant in-trial improvements in risk factor levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: